Aktienanalyse zu Fortrea Holdings Inc (FTRE)FTREFortrea Holdings Inc

Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Fortrea Holdings Inc is a good buy right now, trading at $22.49 with a forward P/E of 12.14, indicating potential for growth relative to earnings. The stock has shown a strong 1-year change of +115.83%, reflecting significant appreciation over the past year. However, the main risk is the insider selling, which has increased by 267.54% over the last month, suggesting potential concerns about the company's future performance.